Compugen
The company IPOed in 2000
GizaVC invests in the vision of Israel's most innovative entrepreneurs.
About
|
Compugen is engaged in the discovery and licensing of product candidates to the drug and diagnostic industry. The company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. To date, Compugen's product discovery efforts and its initial discovery engines have mostly focused on the areas of cancer and immune-related and cardiovascular diseases. Compugen's primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies.
|
 |
|
Compugen went public on Nasdaq in 2000 and on the Tel Aviv Stock Exchange in 2002
|
Corporate Headquarters
Address: 72 Pinchas Rosen St. Tel Aviv, Israel 69512
T: +972-3-765-8585 F: +972-3-765-8555 |
Founders
Simchon Faigler, Amir natan, Eli Mintz
|
Management
President & CEO: Dr. Anat Cohen-Dayag CTO: Dr. Yossi Cohen
CFO: Dikla Czaczkes Axselbrad
|